https://www.selleckchem.com/products/tp-1454.html
vements with umeclidinium/vilanterol versus umeclidinium compared with baseline SABA use 4 puffs/day. In high SABA users, there may be a smaller difference in treatment response between dual- and mono-bronchodilator therapy; the reasons for this require further investigation. SABA use may be a confounding factor in bronchodilator trials and in high SABA users; changes in SABA use may be considered a robust symptom outcome. GlaxoSmithKline (study number 201749 [NCT03034915]). GlaxoSmithKline (study number 201749 [NCT03034915]). The
Respect!
Kommentar
Delen
